Page 1

Q1 INTERIM REPORT Q1 2021 | ACTIVE BIOTECH AB ● FIRST QUARTER IN BRIEF Agreement signed for manufacturing of a topical ophthalmic formulation and capsules of laquinimod for use in clinical studies Active Biotech ● • Activities are ongoing according to plan in the naptumomab and tasquinimod projects FINANCIAL SUMMARY 20204 Financing completed and good progress in the projects EVENTS AFTER THE END OF THE PERIOD Active Biotech and NeoTX announce FDA clearance of IND for phase Il clinical trial of naptumomab SEK M Net sales Operating profit / loss Profit / loss after tax Earnings per share ( SEK ) Cash and cash equivalents ( at close of period ) The report is also available at www.activebiotech.com Corporate Rights issue prospectus published on January 5 , 2021 Rights issue oversubscribed by 175 % and added 76.2 MSEK to liquidity before issue expenses ● ● 2021 Jan - Mar -9.7 -9.8 -0.05 92.0 2020 0.5 -9.7 -10.1 -0.06 47.9 Full - year 2020 6.7 -32.3 -32.2 -0.19 26.2 Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation . This information was provided to the media , through the agency of the contact person set out above , for publication on April 22 , 2021 , at 08.30 a.m. CET . Active Biotech AB ( Corp. reg . no . 556223-9227 ) / Scheelevägen 22 , SE - 223 63 Lund / +46 ( 0 ) 46 19 20 00 / www.activebiotech.com Helén Tuvesson , CEO : +46 ( 0 ) 46 19 21 56 / Hans Kolam , CFO : +46 ( 0 ) 46 19 20 44